Medical speech processing startup Cordio Medical raises $18m to accelerate growth
Cordio Medical's HearO product is a unique disruptive solution that converts a smartphone into a medical-grade device. The smartphone app is backed by sophisticated and proprietary algorithms allowing monitoring and early detection of fluid accumulation related to Congestive Heart Failure (CHF) condition deterioration. After a speech sample is collected from the patient's mobile device, the HearO cloud-based server analyzes the results. If CHF deterioration is discovered, a healthcare professional immediately notifies the patient with an alert.
Tamir Tal, CEO, Cordio Medical: "More than 5.7 million Americans are afflicted with congestive heart failure (CHF), making it one of the most prevalent and costly conditions in the U.S. This latest round of funding will allow Cordio Medical to be at the forefront of the MedTech space as the definitive pioneer in leveraging speech processing technologies to monitor CHF. A smartphone running our app for remote monitoring of CHF status will improve patient mortality, quality of life, and contribute to health economic outcomes."
Ceros Capital Markets, the investment banking division of Ceros Financial Services that focuses on fundraising for early-stage medical technology companies, and Peregrine Ventures, Israel's first dedicated healthcare fund, led the latest funding to support a clinical validation study, health and academic partnerships, and sales team recruitment. The ongoing retail and distribution (R&D) of current and future versions of HearO and clinical operations will be in Israel and the EU.
Mark Goldwasser, CEO, Ceros Financial Services: "Pioneering advancements in medical technology have opened the doors to personalized care with revolutionary new monitoring and treatment options. Cordio Medical's technology for an easy-to-use smartphone app takes patient care to a new level by providing what we believe is the first non-invasive medical-grade monitoring device for chronic heart conditions."
Cordio Medical seeks to go to market in the U.S. in early 2024 with final approval from the FDA.
Eyal Lifschitz, Chairman, Cordio Medical: "HearO is a digital medical device solution that transforms an off-the-shelf mobile device into a personal and accurate diagnostic tool that will help millions of individuals suffering from CHF across the globe while maintaining a firm business model. It has been an exciting journey with Cordio Medical's fantastic team, and we look forward to the company's continued growth."